News

CLN2 Therapy Brineura Gets WORLDSymposium 2018 New Treatment Award

Brineura (cerliponase alfa), marketed by BioMarin Pharmaceuticals, was given the WORLDSymposium 2018 New Treatment Award in recognition of its achievements in treating lysosomal diseases, including Batten disease. Brineura slows the decline of children’s ability to crawl or walk, and is the only therapy approved by the U.S. Food and Drug…

Recommendation Against U.K. Coverage of Brineura Jolts Batten Disease Community

A preliminary recommendation against British National Health Service insurance coverage of the $702,000-a-year therapy Brineura (cerliponase alfa) to treat a specific type of Batten disease is “cruel and inaccurately based,” the U.K. nonprofit Batten Disease Family Association contends. The expensive drug, manufactured by San Francisco-based BioMarin, is aimed…